- cafead   Jun 24, 2024 at 10:52: AM
via Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up regulatory filings.
article source
article source